CDMO Fujifilm Diosynth Biotechnologies will drop $533M (£400M) on an expansion project that will more than double its existing development and manufacturing footprint at its UK facility.
The new multi-modal campus in Billingham, Teesside will include two new state-of-the-art facilities — a viral gene therapy GMP facility and a GMP mammalian cell culture facility.
According to the company, the investment will deliver a ten-fold increase in the CDMO's gene therapy production capabilities from the site. The new cell culture facility will triple existing cell culture capacity capabilities at the UK site.
The expansion is expected to create up to 350 new jobs. The new facilities are expected to be operational by late 2023.
